FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149677053> ?p ?o ?g. }

• W2149677053 endingPage "145" @default.
• W2149677053 startingPage "129" @default.
• W2149677053 abstract "Subjects with moderate combined hyperlipidemia (n=11) were assessed in an investigation of the effects of atorvastatin and simvastatin (both 40 mg per day) on apolipoprotein B (apoB) metabolism. The objective of the study was to examine the mechanism by which statins lower plasma triglyceride levels. Patients were studied on three occasions, in the basal state, after 8 weeks on atorvastatin or simvastatin and then again on the alternate treatment. Atorvastatin produced significantly greater reductions than simvastatin in low density lipoprotein (LDL) cholesterol (49.7 vs. 44.1% decrease on simvastatin) and plasma triglyceride (46.4 vs. 39.4% decrease on simvastatin). ApoB metabolism was followed using a tracer of deuterated leucine. Both drugs stimulated direct catabolism of large very low density lipoprotein (VLDL(1)) apoB (4.52+/-3.06 pools per day on atorvastatin; 5.48+/-4.76 pools per day on simvastatin versus 2.26+/-1.65 pools per day at baseline (both P<0.05)) and this was the basis of the 50% reduction in plasma VLDL(1) concentration; apoB production in this fraction was not significantly altered. On atorvastatin and simvastatin the fractional transfer rates (FTR) of VLDL(1) to VLDL(2) and of VLDL(2) to intermediate density lipoprotein (IDL) were increased significantly, in the latter instance nearly twofold. IDL apoB direct catabolism rose from 0.54+/-0.30 pools per day at baseline to 1.17+/-0.87 pools per day on atorvastatin and to 0.95+/-0.43 pools per day on simvastatin (both P<0.05). Similarly the fractional transfer rate for IDL to LDL conversion was enhanced 58-84% by statin treatment (P<0.01) LDL apoB fractional catabolic rate (FCR) which was low at baseline in these subjects (0.22+/-0.04 pools per day) increased to 0.44+/-0.11 pools per day on atorvastatin and 0.38+/-0.11 pools per day on simvastatin (both P<0.01). ApoB-containing lipoproteins were more triglyceride-rich and contained less free cholesterol and cholesteryl ester on statin therapy. Further, patients on both treatments showed marked decreases in all LDL subfractions. In particular the concentration of small dense LDL (LDL-III) fell 64% on atorvastatin and 45% on simvastatin. We conclude that in patients with moderate combined hyperlipidemia who initially have a low FCR for VLDL and LDL apoB, the principal action of atorvastatin and simvastatin is to stimulate receptor-mediated catabolism across the spectrum of apoB-containing lipoproteins. This leads to a substantial, and approximately equivalent, percentage reduction in plasma triglyceride and LDL cholesterol." @default.
• W2149677053 created "2016-06-24" @default.
• W2149677053 creator A5001160685 @default.
• W2149677053 creator A5003522491 @default.
• W2149677053 creator A5040462138 @default.
• W2149677053 creator A5041604889 @default.
• W2149677053 creator A5048047555 @default.
• W2149677053 creator A5051786674 @default.
• W2149677053 creator A5055699469 @default.
• W2149677053 creator A5058281101 @default.
• W2149677053 date "2002-09-01" @default.
• W2149677053 modified "2023-09-23" @default.
• W2149677053 title "Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates" @default.
• W2149677053 cites W1775749144 @default.
• W2149677053 cites W1974527504 @default.
• W2149677053 cites W1982536995 @default.
• W2149677053 cites W1984845092 @default.
• W2149677053 cites W1985526557 @default.
• W2149677053 cites W2002244930 @default.
• W2149677053 cites W2002306757 @default.
• W2149677053 cites W2005169645 @default.
• W2149677053 cites W2007746673 @default.
• W2149677053 cites W2022698380 @default.
• W2149677053 cites W2028765524 @default.
• W2149677053 cites W2069763849 @default.
• W2149677053 cites W2070779294 @default.
• W2149677053 cites W2080599126 @default.
• W2149677053 cites W2103658595 @default.
• W2149677053 cites W2106536809 @default.
• W2149677053 cites W2109741073 @default.
• W2149677053 cites W2116890637 @default.
• W2149677053 cites W2117950105 @default.
• W2149677053 cites W2123179341 @default.
• W2149677053 cites W2129750583 @default.
• W2149677053 cites W2130576404 @default.
• W2149677053 cites W2150855617 @default.
• W2149677053 cites W2151531707 @default.
• W2149677053 cites W2154447535 @default.
• W2149677053 cites W2155598961 @default.
• W2149677053 cites W2159462455 @default.
• W2149677053 cites W2183983473 @default.
• W2149677053 cites W2186152207 @default.
• W2149677053 cites W2237575611 @default.
• W2149677053 cites W2244527118 @default.
• W2149677053 cites W2260235167 @default.
• W2149677053 cites W2322095705 @default.
• W2149677053 cites W2399967633 @default.
• W2149677053 doi "https://doi.org/10.1016/s0021-9150(02)00052-7" @default.
• W2149677053 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12119202" @default.
• W2149677053 hasPublicationYear "2002" @default.
• W2149677053 type Work @default.
• W2149677053 sameAs 2149677053 @default.
• W2149677053 citedByCount "74" @default.
• W2149677053 countsByYear W21496770532012 @default.
• W2149677053 countsByYear W21496770532014 @default.
• W2149677053 countsByYear W21496770532015 @default.
• W2149677053 countsByYear W21496770532016 @default.
• W2149677053 countsByYear W21496770532017 @default.
• W2149677053 countsByYear W21496770532020 @default.
• W2149677053 countsByYear W21496770532021 @default.
• W2149677053 countsByYear W21496770532022 @default.
• W2149677053 crossrefType "journal-article" @default.
• W2149677053 hasAuthorship W2149677053A5001160685 @default.
• W2149677053 hasAuthorship W2149677053A5003522491 @default.
• W2149677053 hasAuthorship W2149677053A5040462138 @default.
• W2149677053 hasAuthorship W2149677053A5041604889 @default.
• W2149677053 hasAuthorship W2149677053A5048047555 @default.
• W2149677053 hasAuthorship W2149677053A5051786674 @default.
• W2149677053 hasAuthorship W2149677053A5055699469 @default.
• W2149677053 hasAuthorship W2149677053A5058281101 @default.
• W2149677053 hasConcept C126322002 @default.
• W2149677053 hasConcept C134018914 @default.
• W2149677053 hasConcept C185592680 @default.
• W2149677053 hasConcept C2776329913 @default.
• W2149677053 hasConcept C2777482532 @default.
• W2149677053 hasConcept C2778163477 @default.
• W2149677053 hasConcept C2778913445 @default.
• W2149677053 hasConcept C2779091943 @default.
• W2149677053 hasConcept C2780072125 @default.
• W2149677053 hasConcept C555293320 @default.
• W2149677053 hasConcept C62746215 @default.
• W2149677053 hasConcept C71924100 @default.
• W2149677053 hasConcept C8243546 @default.
• W2149677053 hasConceptScore W2149677053C126322002 @default.
• W2149677053 hasConceptScore W2149677053C134018914 @default.
• W2149677053 hasConceptScore W2149677053C185592680 @default.
• W2149677053 hasConceptScore W2149677053C2776329913 @default.
• W2149677053 hasConceptScore W2149677053C2777482532 @default.
• W2149677053 hasConceptScore W2149677053C2778163477 @default.
• W2149677053 hasConceptScore W2149677053C2778913445 @default.
• W2149677053 hasConceptScore W2149677053C2779091943 @default.
• W2149677053 hasConceptScore W2149677053C2780072125 @default.
• W2149677053 hasConceptScore W2149677053C555293320 @default.
• W2149677053 hasConceptScore W2149677053C62746215 @default.
• W2149677053 hasConceptScore W2149677053C71924100 @default.
• W2149677053 hasConceptScore W2149677053C8243546 @default.
• W2149677053 hasIssue "1" @default.
• W2149677053 hasLocation W21496770531 @default.

• next